Biosidus Boosts Manufacturing to Enhance Global Agalsidase Beta Supply

Biosidus, the Argentine biotechnology firm, has announced that its new bioreactor plant is now operational. This expansion aims to increase the company's biologics production capacity, enhancing its potential to meet international demand, especially for agalsidase beta, a biosimilar enzyme replacement therapy for Fabry disease.

This move underscores Biosidus' commitment to providing reliable sources of complex biologic medicines at a time when healthcare systems need assured supply chains. The development and manufacture of agalsidase beta in Argentina mark a vital step for Biosidus' biotechnology platform and its dedication to rare diseases.

Mario Koch, Director of Rare Diseases, emphasized the importance of treatment continuity for rare disease patients and the new capacity aligns with this commitment. The facility is part of a strategy combining scientific prowess, local manufacturing, and industrial investment for broader international expansion.